Key result
NOACs show comparable overall efficacy but specific regimens optimize stroke prevention in AF subgroups.
Why the study?
Does the choice of a specific NOAC or dose improve stroke prevention in specific subgroups of patients with non-valvular atrial fibrillation?
Population
Patients with non-valvular atrial fibrillation in specific clinical subgroups
Comparison
Non-vitamin-K oral anticoagulants (NOACs) vs Vitamin K antagonists (warfarin) or other NOACs
Design
Review
Authors
Loading...
May support prioritizing specific NOACs by subgroup in AF; extends evidence but leaves open confirmation by dedicated trials.
Does the choice of a specific NOAC or dose improve stroke prevention in specific subgroups of patients with non-valvular atrial fibrillation?
This review provides tailored recommendations for selecting specific NOACs and doses for stroke prevention across various clinical subgroups of patients with non-valvular atrial fibrillation.
Diener et al. (2016) conducted a review in non-valvular atrial fibrillation. Non-vitamin-K oral anticoagulants (NOACs) vs. Vitamin K antagonists (warfarin) was evaluated on Stroke and systemic embolism. Non-vitamin-K oral anticoagulants demonstrate similar efficacy and safety in some scenarios, but specific drugs and doses can be prioritized for stroke prevention in certain AF patient subgroups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: